SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ian@SI who wrote (2411)7/4/2005 1:12:52 PM
From: microcapfun   of 3044
 
Velcade seems to have much untapped potential.

My feeling is that Velcade will have little use outside of cancer. The reasoning goes as follows. A multifactorial or 'dirty' offensive is needed in cancer; in most cases simply blocking one target is insufficient. Furthermore in cancer you are willing to put up with a large amount of collateral damage.

In most other non-communicable diseases there is a single pathway at fault and the mutation rate is low. After you fully understand the biology, what you want is a single targeted agent. Also in many cases, e.g. arthritis, you want a drug which can be used continuously for long periods of time if not indefinitely. Significant collateral damage will not be accepted.

So I'll be surprised if Velcade or another proteasome inhibitor turns out to be more than a marginal drug outside of cancer.

Just a speculation.

micro
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News